Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SToP-C: HCV Treatment as Prevention in Prisons
NCT02064049Phase 4Completed
- Sponsor
- The Kirby Institute
- Start
- Oct 2014
- Primary completion
- Nov 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of sofosbuvir + velpatasvir in hepatitis C (HCV) (2 arms), sponsored by The Kirby Institute. Primary endpoint: Hepatitis C virus (HCV) incidence at 2 years. Started Oct 2014; status: completed.
02
Drugs
sofosbuvir + velpatasvir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT02064049.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02064049.